Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Matriptase (ST14, Suppressor of Tumorigenicity 14 Protein)

Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101517

Synonyms

Historical Background

Matriptase is a type II transmembrane serine protease expressed in most types of epithelia (Oberst et al. 2003a). Matriptase was discovered in 1993 as a novel matrix degrading enzyme purified from human breast cancer cells (Shi et al. 1993). Since then, five independent groups have cloned the matriptase cDNA, and the protease has been published under the names membrane-type serine protease 1 (MT-SP1), tumor-associated differentially expressed gene-15 (TADG-15), epithin (in mouse), and SNC19 (Kim et al. 1999; Takeuchi et al. 1999; Cao et al. 2001; Tanimoto et al. 2001). The matriptase gene was given the name suppression of tumorgenecity 14 (ST14) (Zhang et al. 1998).

Matriptase expression studies have been performed in adult human tissue by mRNA, and protein analysis and matriptase expression has been found in all types of epithelium, including columnar, pseudostratified, cuboidal, and squamous (Oberst et al. 2003a). Matriptase expression has also been mapped in mice by enzymatic gene trapping using beta-galactosidase as a reporter, showing that matriptase displays the same overall epithelial expression pattern in mice as in humans (List et al. 2007b). The similar epithelial expression pattern between species suggests that matriptase has a phylogenetically conserved function in mammals.

Matriptase Structure and Activation

From the cloned human cDNA sequence of matriptase, an 855 amino acid (AA) protease with a complex multidomain structure was revealed (Fig. 1a).
Matriptase (ST14, Suppressor of Tumorigenicity 14 Protein), Fig. 1

Structural overview of matriptase and proteolytic processing. (a) Matriptase consists of a transmembrane region (TM domain), a Sea urchin sperm protein, Enterokinase and Agrin (SEA) domain, two C1r/s, Uegf and Bone morphogenic protein (CUB) domains, four low density Lipoprotein Receptor (LDLR) domains, and a serine protease domain (SP domain). (b) Schematic depiction of full-length 95 kDa matriptase (top), SEA domain-cleaved 70 kDa matriptase (middle), and activation site-cleaved matriptase (serine protease domain, 30 kDa) (bottom). Positions of the SEA domain cleavage site (Gly149) and the activation cleavage site (Arg614) are shown with arrowheads.

Matriptase is a type II transmembrane protease characterized by an N-terminal cytoplasmic domain and an extracellular C-terminal. Matriptase does not contain a typical signal peptide, but contains a 26 AA hydrophobic residue (residue 55–81) that is flanked by charged residues on each side, functioning as a membrane signal anchor sequence similar to that of other membrane anchored serine proteases (Takeuchi et al. 1999; Szabo and Bugge 2011). The extracellular region of matriptase contains a single Sea urchin sperm protein Enteropeptidase, Agrin (SEA) domain (residue 85–193), and two Complement factor 1r–Urchin embryonic growth factor-Bone morphogenetic protein (CUB) domains (residues 214–334 and 340–447) (Oberst et al. 2003b). CUB domains have conserved characteristics, which include four cysteine residues and various conserved hydrophobic and aromatic positions. Following the CUB domains are four low-density lipoprotein receptor (LDLR) repeats (residues 452–486, 487–523, 524–561, and 566–604). These repeats have a highly conserved pattern and spacing of six cysteine residues that together form three intramolecular disulfide bonds. The final domain is the serine protease domain (residue 614–855) that contains a substrate specificity pocket (S1 pocket) composed of aspartic acid 627 at its bottom and glycine 655 and glycine 665 at its neck, indicating that matriptase is a trypsin-like serine protease. The residues serine 805, aspartic acid 711, and histidine 656 constitute the catalytic triad and are all crucial for the catalytic activity of matriptase (Perona and Craik 1997). Matriptase has the preferential substrate cleavage site for amino acid residues with positively charged side chains such as arginine and lysine in position P1 (Beliveau et al. 2009). Human matriptase contains four potential sites for N-glycosylation (asparagine in positions 109, 302, 485, and 772) where the glycosylation site in the catalytic domain has been shown to be important for activation of the protease (Oberst et al. 2003b). Matriptase has an intricate multistep activation mechanism. Matriptase is synthesized as a 95 kDa pro-enzyme and full activation of the protease requires two sequential endoproteolytic cleavages (Fig. 1b).

The single chain pro-enzyme contains a consensus cleavage site in the SEA domain (GSVI) that is a target for the first proteolytic processing cleavage. This cleavage converts matriptase to a two-chain form cleaved at glycine 149, yet the processed 70 kDa extracellular domain remains attached to the transmembrane domain. The activation of matriptase zymogen follows a classical scheme by which a canonical activation motif is cleaved to convert a single-chain zymogen into a disulfide-linked two-chain active enzyme. Activated matriptase consists of the 40 kDa stem domain and the serine protease domain of 30 kDa, which is held together by a disulfide bridge. This second proteolytic cleavage takes place at arginine 614 and proteolytic processing of the SEA domain is a prerequisite for the activation site cleavage (Oberst et al. 2003b). Although matriptase is a membrane-associated protease, it was originally purified from the conditioned media from cells and human milk. This is a result of ectodomain shedding, the final proteolytic processing of matriptase. Matriptase can be shed by proteolytic cleavage at lysine 189 and lysine 204, which yields slightly smaller matriptase fragments in the extracellular space than the membrane associated form.

While the activation cleavage for most serine proteases depends on other upstream active proteases, activation of matriptase zymogen appears to be initiated by the weak intrinsic proteolytic activity of the zymogen form, referred to as autoactivation. Mutations in any of the catalytic triad residues (serine 805, aspartic acid 711, and histidine 656) results in a form of matriptase that is cleaved in the SEA domain but is unable to undergo the final activation site cleavage. Furthermore, the noncatalytic domains of matriptase and the posttranslational modifications are required for the activation of matriptase zymogen.

Matriptase in Epithelial Homeostasis

The physiological functions of matriptase have mostly been deduced from the generation of St14 deficient mice. These studies have revealed critical functions of matriptase in the development of multiple epithelial tissues, which is consistent with the species-conserved epithelial expression of the transmembrane serine protease (Fig. 2). Matriptase null mice develop to term showing that the protease does not have critical nonredundant functions in the development of embryonic tissues. However, the mice die shortly after birth due to dehydration caused by an impaired epidermal barrier function (List et al. 2002). Conditional depletion of matriptase in adult mice results in rapid decay of multiple types of epithelia, severe organ dysfunction, and death within nine days. The depletion is associated with increased paracellular permeability, loss of tight junction function, misallocation of tight junction related proteins, and general epithelial demise (List et al. 2009). This demonstrates not just a critical role for matriptase during development of epithelia but also in the maintenance of epithelial homeostasis. Strict control of matriptase activity is also critical for epithelial tissue integrity and function. This was demonstrated in zebrafish where deletion of the cognate inhibitor of matriptase, hepatocyte growth factor activator inhibitor (HAI)-1, expression resulted in disrupted epidermal integrity by loss of cell-cell junctions, hyperproliferation, and inflammation in the skin. These defects could be rescued by the simultaneous deletion of matriptase and HAI-1 (Carney et al. 2007). This was also demonstrated in mice where embryos with a null mutation in the Spint1 gene, encoding HAI-1, die at embryonic day (E) 10, shortly after the onset of matriptase expression at day E8.5, due to disruption of the chorionic membrane in the placenta. The simultaneous deletion of matriptase expression rescued this phenotype and allowed normal placentation and development to term (Szabo et al. 2007). Interestingly, similar defects are observed in mice depleted from the inhibitor HAI-2, highly homologous to HAI-1, where it was shown that HAI-2 is essential for placental development and embryonic survival, and this too could be rescued by simultaneous depletion of matriptase expression (Szabo et al. 2009). Altogether, this demonstrates a delicate balance between the activity of matriptase and the inhibitors HAI-1 and HAI-2 for a favorable proteolytic microenvironment that is conductive to successful tissue morphogenesis. Other inhibitors have been identified in complex with matriptase including antithrombin III, alpha-1-antitrypsin, alpha-2-antiplasmin, and protease nexin-1 (Tseng et al. 2008). Yet the physiological role of serpins in the regulation of matriptase activity has not been elucidated. The need for tight regulation of matriptase activity by inhibitors, as well as the vital role of the protease, underlines that both the absence and the excess of matriptase can cause serious epithelial defects.
Matriptase (ST14, Suppressor of Tumorigenicity 14 Protein), Fig. 2

Matriptase in epithelial homeostasis. Matriptase is essential for epithelial barrier function. The matriptase-prostasin proteolytic cascade processes fibrinogen in to fibrin and maintains cell-cell adhesion. The inhibitors HAI-1 and HAI-2 control the protease activity of matriptase and prostasin and are essential for the epithelial homeostasis.

Prostasin is a GPI-anchored trypsin like serine protease that is involved in the regulation of epithelial sodium channels and is coexpressed with matriptase in most epithelial tissues (List et al. 2007b). Matriptase-deficient mice and prostasin-deficient mice have nearly identical epidermal phenotypes with impaired processing of the epidermis-specific poly-protein pro-filaggrin, compromised epidermal tight junctions, and a lack of terminal epidermal differentiation (Leyvraz et al. 2005). It has been shown in vitro that matriptase is able to cleave the zymogen form of prostasin to generate proteolytically active prostasin. Moreover, only the inactive form of prostasin is found in matriptase-deficient mice and loss of matriptase in primary human keratinocytes is correlated with loss of proteolytic activation of prostasin (Netzel-Arnett et al. 2006). It has also been shown that prostasin is a potent activator of matriptase. However, the ability of prostasin to activate matriptase is independent of its own activity, as both a zymogen-locked and a catalytically inactive form of prostasin can activate matriptase (Friis et al. 2013; Peters et al. 2014; Friis et al. 2016). This indicates that prostasin works as a chaperone, not a protease, for matriptase activation which is consistent with the observation that small molecule protease inhibitors fail to inhibit the matriptase zymogen activation, indicating that no active protease is involved in the process (Oberst et al. 2003b).

Furthermore, the zymogen of matriptase has weak intrinsic activity that is sufficient for activation of prostasin (Friis et al. 2013). This suggests that matriptase and prostasin form a reciprocal activation complex at the pinnacle of the protease cascade, and initiation of the cascade is facilitated by the interaction of the pro-forms of matriptase and prostasin which activates each other.

Matriptase in Epithelial Pathology and Cancer

A rare mutation in the ST14 gene causes a form of the skin disease ichthyosis with hypotrichosis syndrome in humans characterized by scaly skin and abnormal hair (Basel-Vanagaite et al. 2007). This is caused by a mutation in the serine protease domain of matriptase at glycine 827, which results in strongly reduced matriptase activity and consequently a lack of prostasin activation (Desilets et al. 2008). The ichthyosis symptoms are phenocopied in matriptase hypomorphic mice with a 100-fold reduction in epidermal matriptase mRNA levels showing impaired desquamation and brittle thin hair (List et al. 2007a). Recently matriptase has been coupled to another form of ichthyosis seen in the skin disease Netherton Syndrome, where matriptase is capable of initiating premature activation of a pro-kallikrein-related cascade and in the protease inhibitor LEKTI-deficient mice. Additionally, increased matriptase expression has been observed in keratinocytes at the site of inflammation in 16 different skin diseases (Chen et al. 2011).

Matriptase is expressed with consistency in human tumors of diverse epithelial origin and in cell lines derived from these tumors. Several studies have assessed the level of expression of matriptase during malignant progression and the prognostic value of matriptase in various human cancers. In vivo studies have shown that matriptase possesses a strong oncogenic potential when unopposed by its inhibitor HAI-1. Modest overexpression of matriptase in the skin of mice caused spontaneous squamous cell carcinoma and dramatically potentiated carcinogen-induced tumor formation. A simultaneous increase in epidermal HAI-1 expression completely negated the oncogenic effects of matriptase highlighting the importance of inhibition by HAI-1 for proper epithelial homeostasis (List et al. 2005). Molecular analysis revealed that spatial deregulation of matriptase leads to the activation of the c-Met-Akt signaling pathway and that ablation of the oncogene c-Met negated the oncogenic potential of matriptase in mice. In addition, matriptase-dependent carcinoma formation was blocked by inhibition of the Akt-pathway, identifying matriptase as an essential component of c-Met induced carcinogenesis (List et al. 2005; Szabo et al. 2011). It is also noteworthy that other candidate substrates for matriptase are implicated in matriptase-induced malignant progression, including the G-protein coupled protease-activated receptor-2 (par-2) where genetic elimination of PAR-2 completely prevented premalignant progression, including inflammatory cytokine production, inflammatory cell recruitment, epidermal hyperplasia, and dermal fibrosis (Sales et al. 2015) (Fig. 3).
Matriptase (ST14, Suppressor of Tumorigenicity 14 Protein), Fig. 3

Matriptase in cancer. Matriptase is a potent oncogene and is widely expressed in most epithelial cancers. A slight overexpression of matriptase activity promotes the carcinogenesis through the tyrosine kinase cMet and the PI3K-akt pathway as matriptase is an efficient activator of pro-hepatocyte growth factor (HGF)/Scatter factor (SF). Matriptase also activates the G-protein coupled receptor protease activated receptor (Par-2) which regulates inflammatory response through the transcription factor NFκB.

Summary

Matriptase is a type II transmembrane serine protease expressed in most types of epithelia. Matriptase has been shown to play a crucial role in epithelial homeostasis as matriptase-deficient mice and humans have severe epithelial barrier defects. Matriptase is situated at the pinnacle of a protease cascade that is involved in epidermal differentiation and pro-filaggrin processing. The GPI-anchored serine protease prostasin acts as a chaperone for matriptase activation, as prostasin can activate matriptase, however independent of the proteolytic activity of prostasin. Matriptase has been shown to be a potent oncogene when unopposed by its cognate inhibitor HAI-1. Matriptase exerts its oncogenic functions through the cMet-akt pathway and through the G-protein coupled receptor Par-2. The need for tight regulation of matriptase activity by inhibitors, as well as the vital role of the protease, underlines that both the absence and the excess of matriptase can cause serious epithelial defects.

References

  1. Basel-Vanagaite L, Attia R, Ishida-Yamamoto A, Rainshtein L, Ben Amitai D, Lurie R, et al. Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase. Am J Hum Genet. 2007;80:467–77. doi: 10.1086/512487.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Beliveau F, Desilets A, Leduc R. Probing the substrate specificities of matriptase, matriptase-2, hepsin and DESC1 with internally quenched fluorescent peptides. FEBS J. 2009;276:2213–26. doi: 10.1111/j.1742-4658.2009.06950.x.PubMedCrossRefGoogle Scholar
  3. Cao J, Zheng S, Zheng L, Cai X, Zhang Y, Geng L, et al. A novel serine protease SNC19 associated with human colorectal cancer. Chin Med J (Engl). 2001;114:726–30.Google Scholar
  4. Carney TJ, von der Hardt S, Sonntag C, Amsterdam A, Topczewski J, Hopkins N, et al. Inactivation of serine protease Matriptase1a by its inhibitor Hai1 is required for epithelial integrity of the zebrafish epidermis. Development. 2007;134:3461–71. doi: 10.1242/dev.004556.PubMedCrossRefGoogle Scholar
  5. Chen CJ, Wu BY, Tsao PI, Chen CY, Wu MH, Chan YL, et al. Increased matriptase zymogen activation in inflammatory skin disorders. Am J Phys Cell Physiol. 2011;300:C406–15. doi: 10.1152/ajpcell.00403.2010.CrossRefGoogle Scholar
  6. Desilets A, Beliveau F, Vandal G, McDuff FO, Lavigne P, Leduc R. Mutation G827R in matriptase causing autosomal recessive ichthyosis with hypotrichosis yields an inactive protease. J Biol Chem. 2008;283:10535–42. doi: 10.1074/jbc.M707012200.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Friis S, Madsen DH, Bugge TH. Distinct developmental functions of prostasin (CAP1/PRSS8) zymogen and activated prostasin. J Biol Chem. 2016;291:2577–82. doi: 10.1074/jbc.C115.706721.PubMedCrossRefGoogle Scholar
  8. Friis S, Uzzun Sales K, Godiksen S, Peters DE, Lin CY, Vogel LK, et al. A matriptase-prostasin reciprocal zymogen activation complex with unique features: prostasin as a non-enzymatic co-factor for matriptase activation. J Biol Chem. 2013;288:19028–39. doi: 10.1074/jbc.M113.469932.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Kim MG, Chen C, Lyu MS, Cho EG, Park D, Kozak C, et al. Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics. 1999;49:420–8.PubMedCrossRefGoogle Scholar
  10. Leyvraz C, Charles RP, Rubera I, Guitard M, Rotman S, Breiden B, et al. The epidermal barrier function is dependent on the serine protease CAP1/Prss8. J Cell Biol. 2005;170:487–96. doi: 10.1083/jcb.200501038.PubMedPubMedCentralCrossRefGoogle Scholar
  11. List K, Currie B, Scharschmidt TC, Szabo R, Shireman J, Molinolo A, et al. Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice. J Biol Chem. 2007a;282:36714–23. doi: 10.1074/jbc.M705521200.PubMedCrossRefGoogle Scholar
  12. List K, Haudenschild CC, Szabo R, Chen W, Wahl SM, Swaim W, et al. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene. 2002;21:3765–79. doi: 10.1038/sj.onc.1205502.PubMedCrossRefGoogle Scholar
  13. List K, Hobson JP, Molinolo A, Bugge TH. Co-localization of the channel activating protease prostasin/(CAP1/PRSS8) with its candidate activator, matriptase. J Cell Physiol. 2007b;213:237–45. doi: 10.1002/jcp.21115.PubMedCrossRefGoogle Scholar
  14. List K, Kosa P, Szabo R, Bey AL, Wang CB, Molinolo A, et al. Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. Am J Pathol. 2009;175:1453–63. doi: 10.2353/ajpath.2009.090240.PubMedPubMedCentralCrossRefGoogle Scholar
  15. List K, Szabo R, Molinolo A, Sriuranpong V, Redeye V, Murdock T, et al. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev. 2005;19:1934–50. doi: 10.1101/gad.1300705.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Netzel-Arnett S, Currie BM, Szabo R, Lin CY, Chen LM, Chai KX, et al. Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J Biol Chem. 2006;281:32941–5. doi: 10.1074/jbc.C600208200.PubMedCrossRefGoogle Scholar
  17. Oberst MD, Singh B, Ozdemirli M, Dickson RB, Johnson MD, Lin CY. Characterization of matriptase expression in normal human tissues. J Histochem Cytochem. 2003a;51:1017–25.PubMedCrossRefGoogle Scholar
  18. Oberst MD, Williams CA, Dickson RB, Johnson MD, Lin CY. The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem. 2003b;278:26773–9. doi: 10.1074/jbc.M304282200.PubMedCrossRefGoogle Scholar
  19. Perona JJ, Craik CS. Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. J Biol Chem. 1997;272:29987–90.PubMedCrossRefGoogle Scholar
  20. Peters DE, Szabo R, Friis S, Shylo NA, Uzzun Sales K, Holmbeck K, et al. The membrane-anchored serine protease prostasin (CAP1/PRSS8) supports epidermal development and postnatal homeostasis independent of its enzymatic activity. J Biol Chem. 2014;289:14740–9. doi: 10.1074/jbc.M113.541318.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Sales KU, Friis S, Konkel JE, Godiksen S, Hatakeyama M, Hansen KK, et al. Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis. Oncogene. 2015;34:346–56. doi: 10.1038/onc.2013.563.PubMedCrossRefGoogle Scholar
  22. Shi YE, Torri J, Yieh L, Wellstein A, Lippman ME, Dickson RB. Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res. 1993;53:1409–15.PubMedGoogle Scholar
  23. Szabo R, Bugge TH. Membrane-anchored serine proteases in vertebrate cell and developmental biology. Annu Rev Cell Dev Biol. 2011;27:213–35. doi: 10.1146/annurev-cellbio-092910-154247.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Szabo R, Hobson JP, Christoph K, Kosa P, List K, Bugge TH. Regulation of cell surface protease matriptase by HAI2 is essential for placental development, neural tube closure and embryonic survival in mice. Development. 2009;136:2653–63. doi: 10.1242/dev.038430.PubMedPubMedCentralCrossRefGoogle Scholar
  25. Szabo R, Molinolo A, List K, Bugge TH. Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development. Oncogene. 2007;26:1546–56. doi: 10.1038/sj.onc.1209966.PubMedCrossRefGoogle Scholar
  26. Szabo R, Rasmussen AL, Moyer AB, Kosa P, Schafer JM, Molinolo AA, et al. c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene. 2011;30:2003–16. doi: 10.1038/onc.2010.586.PubMedPubMedCentralCrossRefGoogle Scholar
  27. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci U S A. 1999;96:11054–61.PubMedPubMedCentralCrossRefGoogle Scholar
  28. Tanimoto H, Underwood LJ, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ. Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol. 2001;22:104–14. doi:50604PubMedCrossRefGoogle Scholar
  29. Tseng IC, Chou FP, Su SF, Oberst M, Madayiputhiya N, Lee MS, et al. Purification from human milk of matriptase complexes with secreted serpins: mechanism for inhibition of matriptase other than HAI-1. Am J Phys Cell Physiol. 2008;295:C423–31. doi: 10.1152/ajpcell.00164.2008.CrossRefGoogle Scholar
  30. Zhang Y, Cai X, Schlegelberger B, Zheng S. Assignment1 of human putative tumor suppressor genes ST13 (alias SNC6) and ST14 (alias SNC19) to human chromosome bands 22q13 and 11q24-->q25 by in situ hybridization. Cytogenet Cell Genet. 1998;83:56–7. doi:15125PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Institute for Veterinary Disease Biology, Section for Molecular Disease BiologyUniversity of CopenhagenCopenhagenDenmark